SCHEMBL13562467

SCHEMBL13562467

Cc1ccc(Cc2ccccc2Cl)nn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 1/20 0.47
TAAR1 Q96RJ0 2/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
P2RX7 Q99572 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
PNMT P11086 1/20 0.39
IDO1 P14902 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18762379 0.84 TAAR1 (0.47) SLC5A2TAAR1HTR2CHTR2BLMNA
SCHEMBL15926016 0.81 TAAR1 (0.39) SLC5A2TAAR1LMNAALDH1A1MEN1
SCHEMBL13561334 0.78 SLC5A2 (0.50) SLC5A2TAAR1HTR2CHTR2BLMNA
SCHEMBL13562465 0.76 HTR2C (0.50) TAAR1HTR2CLMNAALDH1A1MAPT
SCHEMBL13051982 0.76 APLNR (0.39) SLC5A2LMNARAB9AALDH1A1
SCHEMBL9846059 0.75 ADORA2A (0.46) TAAR1HTR2CHTR2BADORA2AADORA1
SCHEMBL13562419 0.74 CYP1A2 (0.46) TAAR1HTR2CHTR2BLMNAADORA2A
SCHEMBL9026500 0.74 SMN1; SMN2 (0.50) TAAR1HTR2CHTR2BLMNAADORA2A
SCHEMBL13562417 0.74 P2RX7 (0.41) TAAR1HTR2CHTR2BSMN1; SMN2ALDH1A1
SCHEMBL13562414 0.73 ALDH1A1 (0.60) TAAR1HTR2CRAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751890-B2 Heteroaryl derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-05 US disclosed
US-20170107225-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2017-04-20 US disclosed
US-8299099-B2 Heteroaryl derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-30 US disclosed
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107225-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS CFTR, ABCB1, ABCD3 SLC5A2 452/4885TAAR1 3888/4885HTR2C 3279/4885
US-20090221597-A1 HETEROARYL DERIVATIVES AS CFTR MODULATORS CFTR, ABCB1, ABCD3 SLC5A2 572/4885TAAR1 3974/4885HTR2C 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.